key: cord-0992278-wr0regqt
authors: Wiegand, Sarah E.; Mitchell, Wendy G.; Santoro, Jonathan D.
title: Immunotherapy Responsive SARS-CoV-2 Infection Exacerbating Opsoclonus Myoclonus Syndrome
date: 2021-02-23
journal: Mult Scler Relat Disord
DOI: 10.1016/j.msard.2021.102855
sha: 5f7dba09f4119bd99bf9c8a7ec9627f839d94604
doc_id: 992278
cord_uid: wr0regqt

The global pandemic of SARS-CoV-2 has been known to have diverse neurologic complications among adult patients. The neurologic effects of SARS-CoV-2 in the pediatric population is poorly described, especially in those with rare underlying neurologic conditions. We describe the first known case of SARS-CoV-2 in a pediatric patient with refractory opsoclonus-myoclonus syndrome. A 25-month-old female with progressive opsoclonus-myoclonus syndrome secondary to metastatic neuroblastoma status-post resection and chemotherapy presented with worsening opsoclonus, tremor, and breakthrough seizures. She had no fever or respiratory symptoms at presentation. Urine catecholamines were unchanged, with low suspicion for tumor recurrence. She was found to have SARS-CoV-2 via nasopharnygeal PCR assay. She received intravenous immunoglobulin and dexamethasone therapy with improvement in opsoclonus-myoclonus syndrome symptoms and was discharged home at her neurologic baseline. Patients with opsoclonus-myoclonus syndrome may present with exacerbation of symptoms in the context of SARS-CoV-2. This case describes a sentinel report of a child with opsoclonus-myoclonus syndrome presenting with worsening symptoms with concomitant SARS-CoV-2. Improvement in symptoms was achieved with standard of care therapies.

The global pandemic of SARS-CoV-2 has been known to have diverse neurologic complications among adult patients. The neurologic effects of SARS-CoV-2 in the pediatric population is poorly described, especially in those with rare underlying neurologic conditions. We describe the first known case of SARS-CoV-2 in a pediatric patient with refractory opsoclonus-myoclonus syndrome. A 25-month-old female with progressive opsoclonus-myoclonus syndrome secondary to metastatic neuroblastoma status-post resection and chemotherapy presented with worsening opsoclonus, tremor, and breakthrough seizures. She had no fever or respiratory symptoms at presentation. Urine catecholamines were unchanged, with low suspicion for tumor recurrence.

She was found to have SARS-CoV-2 via nasopharnygeal PCR assay. She received intravenous immunoglobulin and dexamethasone therapy with improvement in opsoclonus-myoclonus syndrome symptoms and was discharged home at her neurologic baseline. Patients with opsoclonus-myoclonus syndrome may present with exacerbation of symptoms in the context of SARS-CoV-2. This case describes a sentinel report of a child with opsoclonus-myoclonus syndrome presenting with worsening symptoms with concomitant SARS-CoV-2. Improvement in symptoms was achieved with standard of care therapies.

SARS-CoV-2 has primarily manifested as respiratory illness, however description of neurologic complications are now being reported. 1,2 Children are frequently asymptomatic or mildly symptomatic with fever and respiratory symptoms, 3 and rarely have neurologic manifestations. An Italian pediatric cohort reported that only 4% complained of headaches, with no other neurologic symptoms. 4 Little is known regarding the impact of SARS-CoV-2 in children with neurological disorders, especially those on the neuroimmunologic disease. Opsoclonus-myoclonus syndrome (OMS) is an autoimmune, presumably B-cell mediated, paraneoplastic disorder which primarily affects children.

Infections have been associated with provocation of OMS symptoms. 5 Here the authors present a case of SARS-CoV-2 associated worsening of OMS in a young child.

A 25-month-old female with a history of OMS secondary to metastatic neuroblastoma (diagnosed with opsoclonus and neuroblastoma at age 13 months, statuspost resection and chemotherapy, with wean of immunotherapy five months prior to presentation), and epilepsy, presented with worsening of opsoclonus, ataxia, and concern for seizure. Four days prior to presentation, the patient was febrile (38° C) and had multiple family members with viral respiratory symptoms, all who had negative SARS-CoV-2 PCR testing. On presentation, the patient was postictal with a neurological exam notable for opsoclonus and ataxia, worsened from baseline (Table 1) . Screening labs, chest radiograph, CT head and MRI brain were unremarkable. Due to concern for seizures, she received two doses of lorazepam and levetiracetam loading dose and remained seizure free. SARS-CoV-2 PCR assay was obtained upon admission and was positive. Her mental status improved but she continued to have marked opsoclonus and ataxia.

Once admitted, she underwent multidisciplinary evaluation. Urine catecholamines were unchanged and a metaiodobenzylguanidine (MIBG) I-123 scan demonstrated an absolute Curie score 0, making worsening symptoms secondary to relapse unlikely.

Additional infectious studies were unrevealing including adenovirus, coxsackievirus, enterovirus, haemophillus influenza, influenza A/B, mycoplasma pneuomniae, parechovirus, parainfluenza, and rhinovirus. Lumbar puncture was not obtained.

On hospital day three (seven days after onset of fever, four days after onset of neurologic symptoms), the patient received intravenous immunoglobulin (2g/kg over 2 days) and a three day pulse dose of dexamethasone with return to her neurologic baseline over 48 hours. The patient has remained at her neurologic baseline at her six month follow up.

We report a patient with known OMS found to be infected with the novel virus SARS-CoV-2. The primary complaint prompting emergent evaluation was not related to infectious symptoms, but rather worsening of her baseline OMS symptoms and a seizurelike event. Interestingly, while the patient did have fever at onset of her symptoms, they were otherwise asymptomatic from a respiratory standpoint and had a negative chest radiograph. Given our patient's infection with SARS-CoV-2, this virus should be considered a potential trigger of relapse in patients with paraneoplastic or neuroimmunologic phenomena even when systemic infectious symptoms are not present.

Although CSF analysis would be ideal for this patient, data on CSF tested for SARS-CoV-2 has been reported to be negative in all cases to this point. 2 Worsening of baseline OMS has been previously reported in children with a variety of viral infections, although members of the coronaviridae family have not been exclusively reported. 6 Of note, post-infectious opsoclonus has been reported, often in older individuals without a history of paraneoplastic OMS. 7 In this case, there would be no mechanism to distinguish if SARS-CoV-2 caused a post-infectious opsoclonus although the short time course between fever and opsoclonus and her past medical history make this less likely.

Similarly, other immune mediated phenomenon such as Guillain Barre syndrome have been reported in following infection with SARS-CoV-2 although these have predominantly been in adults without a history of neuroimmunologic disorders such as OMS. 8 The spike protein of SARS-CoV-2 has been hypothesized to be a trigger for autoimmune responses although definitive correlation remains elusive. Although novel in the report of SARS-CoV-2 exacerbating OMS, this report must also be tempered in that other viruses have also been linked to this phenomenon in pediatric patients. 6 Management of exacerbations of paraneoplastic and neuroimmune mediated neurological conditions during this pandemic should include standard of care immunomodulating therapies, preferably administered quickly following identification of SARS-CoV-2 status, although further large-scale study is needed. Stance -0: standing and sitting balance normal for age Gait -1: mildly wide-based gait for age, but able to walk indoors and outdoors independently Arm/hand function -1: mild, infrequent tremor or jerkiness without functional impairment Opsoclonus -1: rare or only when elicited by change in fixation or "squeeze test" Mood/Behavior -0: normal Speech -1: mildly unclear, plateaued in development

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in wuhan, china

Neurologic features in severe SARS-CoV-2 infection

SARS-CoV-2 infection in children

Coronavirus Infection in Pediatric Emergency Departments (CONFIDENCE) Research Group. Children with covid-19 in pediatric emergency departments in italy

Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome

Trends and tenets in relapsing and progressive opsoclonusmyoclonus syndrome

Infection-Associated Opsoclonus: A Retrospective Case Record Analysis and Review of Literature

Guillain-Barré syndrome associated with SARS-CoV-2 infection. Comments after 16 published cases

The authors have no acknowledgements.

Age 25 months: At presentation with COVID-19 infection 10 Stance -1: mildly unstable standing for age, slightly wide based Gait -2: walks only or predominantly with support from person or equipment Arm/hand function -2: fine motor function persistently impaired for age, but less precise manipulative tasks normal or almost normal Opsoclonus -2: Frequent, interferes intermittently with fixation or tracking Mood/Behavior -1: mild increase in irritability but consolable; and/or mild sleep disturbances Speech -2: loss of some words or some grammatical constructs (i.e. from sentences to phrases) but still communicates verbally